The complexities of obesity and diabetes with the development and progression of pancreatic cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1815, Issue 2, 2011, Pages 135-146

  Bao, Bin ^a   Wang, Zhiwei ^a   Li, Yiwei ^a   Kong, Dejuan ^a   Ali, Shadan ^b   Banerjee, Sanjeev ^a   Ahmad, Aamir ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Diabetes mellitus; Metformin; Obesity; Pancreatic cancer; TZD

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; METFORMIN; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SEX HORMONE; SOMATOMEDIN C RECEPTOR;

ADIPOSE TISSUE; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; DIABETES MELLITUS; DIABETOGENESIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE METABOLISM; HIGH RISK POPULATION; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; HYPOXEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

DIABETES COMPLICATIONS; DISEASE PROGRESSION; HUMANS; INSULIN RESISTANCE; OBESITY; PANCREATIC NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 78651355589     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.11.003     Document Type: Review

References (246)

1. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl Cancer Inst. 2005, 97:1407-1427.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
3. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
4. Arslan A.A., Helzlsouer K.J., Kooperberg C., Shu X.O., Steplowski E., Bueno-de-Mesquita H.B., Fuchs C.S., Gross M.D., Jacobs E.J., Lacroix A.Z., Petersen G.M., Stolzenberg-Solomon R.Z., Zheng W., Albanes D., Amundadottir L., Bamlet W.R., Barricarte A., Bingham S.A., Boeing H., Boutron-Ruault M.C., Buring J.E., Chanock S.J., Clipp S., Gaziano J.M., Giovannucci E.L., Hankinson S.E., Hartge P., Hoover R.N., Hunter D.J., Hutchinson A., Jacobs K.B., Kraft P., Lynch S.M., Manjer J., Manson J.E., McTiernan A., McWilliams R.R., Mendelsohn J.B., Michaud D.S., Palli D., Rohan T.E., Slimani N., Thomas G., Tjonneland A., Tobias G.S., Trichopoulos D., Virtamo J., Wolpin B.M., Yu K., Zeleniuch-Jacquotte A., Patel A.V. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Intern. Med. 2010, 170:791-802.
5. Lowenfels A.B., Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematol. Oncol. Clin. North Am. 2002, 16:1-16.
6. Lowenfels A.B., Sullivan T., Fiorianti J., Maisonneuve P. The epidemiology and impact of pancreatic diseases in the United States. Curr. Gastroenterol. Rep. 2005, 7:90-95.
7. Michaud D.S. Epidemiology of pancreatic cancer. Minerva Chir. 2004, 59:99-111.
8. Schuster D.P. Obesity and the Development of Type 2 Diabetes: The Effects of Fatty Tissue Inflammation 2010, 253-262. Dovepress.
9. WHO, World Health Organization Fact Sheet for World Wide Prevalence of Obesity, 2006. http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
10. Chang S., Masse L.C., Moser R.P., Dodd K.W., Arganaraz F., Fuemmler B.F., Jemal A. State ranks of incident cancer burden due to overweight and obesity in the United States, 2003. Obesity (Silver, Spring) 2008, 16:1636-1650.
11. Flegal K.M., Carroll M.D., Kuczmarski R.J., Johnson C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metab. Disord. 1998, 22:39-47.
12. Energy and Protein Requirements: Report of a Joint Expert Consultation 1985, FAO/WHO/UN, WHO, Geneva.
13. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
14. Anderson A.S., Caswell S. Obesity management-an opportunity for cancer prevention. Surgeon 2009, 7:282-285.
15. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002, 3:565-574.
16. bu-Abid S., Szold A., Klausner J. Obesity and cancer. J. Med. 2002, 33:73-86.
17. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
18. Gumbs A.A. Obesity, pancreatitis, and pancreatic cancer. Obes. Surg. 2008, 18:1183-1187.
19. Hsing A.W., Sakoda L.C., Chua S. Obesity, metabolic syndrome, and prostate cancer. Am. J. Clin. Nutr. 2007, 86:s843-s857.
20. Kuriyama S., Tsubono Y., Hozawa A., Shimazu T., Suzuki Y., Koizumi Y., Suzuki Y., Ohmori K., Nishino Y., Tsuji I. Obesity and risk of cancer in Japan. Int. J. Cancer 2005, 113:148-157.
21. Percik R., Stumvoll M. Obesity and cancer. Exp. Clin. Endocrinol. Diabetes 2009, 117:563-566.
22. Pischon T., Nothlings U., Boeing H. Obesity and cancer. Proc. Nutr. Soc. 2008, 67:128-145.
23. Teucher B., Rohrmann S., Kaaks R. Obesity: focus on all-cause mortality and cancer. Maturitas 2010, 65:112-116.
24. de Berrington G.A., Spencer E.A., Bueno-de-Mesquita H.B., Roddam A., Stolzenberg-Solomon R., Halkjaer J., Tjonneland A., Overvad K., Clavel-Chapelon F., Boutron-Ruault M.C., Boeing H., Pischon T., Linseisen J., Rohrmann S., Trichopoulou A., Benetou V., Papadimitriou A., Pala V., Palli D., Panico S., Tumino R., Vineis P., Boshuizen H.C., Ocke M.C., Peeters P.H., Lund E., Gonzalez C.A., Larranaga N., Martinez-Garcia C., Mendez M., Navarro C., Quiros J.R., Tormo M.J., Hallmans G., Ye W., Bingham S.A., Khaw K.T., Allen N., Key T.J., Jenab M., Norat T., Ferrari P., Riboli E. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev. 2006, 15:879-885.
25. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348:1625-1638.
26. Friedman G.D., van den Eeden S.K. Risk factors for pancreatic cancer: an exploratory study. Int. J. Epidemiol. 1993, 22:30-37.
27. Gapstur S.M., Gann P.H., Lowe W., Liu K., Colangelo L., Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000, 283:2552-2558.
28. Isaksson B., Jonsson F., Pedersen N.L., Larsson J., Feychting M., Permert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish Twin Registry. Int. J. Cancer 2002, 98:480-482.
29. Larsson S.C., Permert J., Hakansson N., Naslund I., Bergkvist L., Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br. J. Cancer 2005, 93:1310-1315.
30. Michaud D.S., Giovannucci E., Willett W.C., Colditz G.A., Stampfer M.J., Fuchs C.S. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286:921-929.
31. Patel A.V., Rodriguez C., Bernstein L., Chao A., Thun M.J., Calle E.E. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol. Biomarkers Prev. 2005, 14:459-466.
32. Rapp K., Schroeder J., Klenk J., Stoehr S., Ulmer H., Concin H., Diem G., Oberaigner W., Weiland S.K. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br. J. Cancer 2005, 93:1062-1067.
33. Shibata A., Mack T.M., Paganini-Hill A., Ross R.K., Henderson B.E. A prospective study of pancreatic cancer in the elderly. Int. J. Cancer 1994, 58:46-49.
34. Howe G.R., Jain M., Miller A.B. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. Int. J. Cancer 1990, 45:604-608.
35. Nilsen T.I., Vatten L.J. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes Control 2000, 11:645-652.
36. Zatonski W., Przewozniak K., Howe G.R., Maisonneuve P., Walker A.M., Boyle P. Nutritional factors and pancreatic cancer: a case-control study from south-west Poland. Int. J. Cancer 1991, 48:390-394.
37. de Berrington G.A., Sweetland S., Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br. J. Cancer 2003, 89:519-523.
38. Larsson S.C., Orsini N., Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int. J. Cancer 2007, 120:1993-1998.
39. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
40. Luo J., Margolis K.L., Adami H.O., LaCroix A., Ye W. Obesity and risk of pancreatic cancer among postmenopausal women: the Women's Health Initiative (United States). Br. J. Cancer 2008, 99:527-531.
41. Li D., Morris J.S., Liu J., Hassan M.M., Day R.S., Bondy M.L., Abbruzzese J.L. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301:2553-2562.
42. Jiao L., de Berrington G.A., Hartge P., Pfeiffer R.M., Park Y., Freedman D.M., Gail M.H., Alavanja M.C., Albanes D., Beane Freeman L.E., Chow W.H., Huang W.Y., Hayes R.B., Hoppin J.A., Ji B.T., Leitzmann M.F., Linet M.S., Meinhold C.L., Schairer C., Schatzkin A., Virtamo J., Weinstein S.J., Zheng W., Stolzenberg-Solomon R.Z. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control 2010, 21:1305-1314.
43. Johansen D., Stocks T., Jonsson H., Lindkvist B., Bjorge T., Concin H., Almquist M., Haggstrom C., Engeland A., Ulmer H., Hallmans G., Selmer R., Nagel G., Tretli S., Stattin P., Manjer J. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2307-2317.
44. Godsland I.F. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. (Lond) 2010, 118:315-332.
45. Kahn B.B., Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 2000, 106:473-481.
46. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch. Physiol. Biochem. 2008, 114:63-70.
47. Jazet I.M., Pijl H., Meinders A.E. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth. J. Med. 2003, 61:194-212.
48. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
49. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
50. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch. Physiol. Biochem. 2009, 115:86-96.
51. Boyd D.B. Insulin and cancer. Integr. Cancer Ther. 2003, 2:315-329.
52. Fisher W.E., Boros L.G., Schirmer W.J. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J. Surg. Res. 1996, 63:310-313.
53. McCarty M.F. Insulin secretion as a determinant of pancreatic cancer risk. Med. Hypotheses 2001, 57:146-150.
54. Pannala R., Basu A., Petersen G.M., Chari S.T. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10:88-95.
55. Stolzenberg-Solomon R.Z., Graubard B.I., Chari S., Limburg P., Taylor P.R., Virtamo J., Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005, 294:2872-2878.
56. Mossner J., Logsdon C.D., Goldfine I.D., Williams J.A. Do insulin and the insulin like growth factors (IGFs) stimulate growth of the exocrine pancreas?. Gut 1987, 28(SUPPL):51-55.
57. Conover C.A., Lee P.D., Kanaley J.A., Clarkson J.T., Jensen M.D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J. Clin. Endocrinol. Metab. 1992, 74:1355-1360.
58. Kaaks R., Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr. Soc. 2001, 60:91-106.
59. Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found. Symp. 2004, 262:247-260.
60. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
61. Verheus M., Peeters P.H., Rinaldi S., Dossus L., Biessy C., Olsen A., Tjonneland A., Overvad K., Jeppesen M., Clavel-Chapelon F., Tehard B., Nagel G., Linseisen J., Boeing H., Lahmann P.H., Arvaniti A., Psaltopoulou T., Trichopoulou A., Palli D., Tumino R., Panico S., Sacerdote C., Sieri S., van Gils C.H., Bueno-de-Mesquita B.H., Gonzalez C.A., Ardanaz E., Larranaga N., Garcia C.M., Navarro C., Quiros J.R., Key T., Allen N., Bingham S., Khaw K.T., Slimani N., Riboli E., Kaaks R. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int. J. Cancer 2006, 119:659-667.
62. Wei E.K., Ma J., Pollak M.N., Rifai N., Fuchs C.S., Hankinson S.E., Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol. Biomarkers Prev. 2005, 14:850-855.
63. Engeli S., Feldpausch M., Gorzelniak K., Hartwig F., Heintze U., Janke J., Mohlig M., Pfeiffer A.F., Luft F.C., Sharma A.M. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52:942-947.
64. Straczkowski M., Kowalska I., Stepien A., Dzienis-Straczkowska S., Szelachowska M., Kinalska I. Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diab. Care 2002, 25:1824-1828.
65. Khalili P., Flyvbjerg A., Frystyk J., Lundin F., Jendle J., Engstrom G., Nilsson P.M. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study. Diabetes Metab. 2010, 36:137-143.
66. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
67. Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diab. Care 2003, 26:2442-2450.
68. Swarbrick M.M., Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 2008, 6:87-102.
69. Krakoff J., Funahashi T., Stehouwer C.D., Schalkwijk C.G., Tanaka S., Matsuzawa Y., Kobes S., Tataranni P.A., Hanson R.L., Knowler W.C., Lindsay R.S. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diab. Care 2003, 26:1745-1751.
70. Samaras K., Botelho N.K., Chisholm D.J., Lord R.V. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver, Spring) 2010, 18:884-889.
71. Viljanen A.P., Lautamaki R., Jarvisalo M., Parkkola R., Huupponen R., Lehtimaki T., Ronnemaa T., Raitakari O.T., Iozzo P., Nuutila P. Effects of weight loss on visceral and abdominal subcutaneous adipose tissue blood-flow and insulin-mediated glucose uptake in healthy obese subjects. Ann. Med. 2009, 41:152-160.
72. Dalamaga M., Migdalis I., Fargnoli J.L., Papadavid E., Bloom E., Mitsiades N., Karmaniolas K., Pelecanos N., Tseleni-Balafouta S., Onyssiou-Asteriou A., Mantzoros C.S. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 2009, 20:625-633.
73. Stolzenberg-Solomon R.Z., Weinstein S., Pollak M., Tao Y., Taylor P.R., Virtamo J., Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am. J. Epidemiol. 2008, 168:1047-1055.
74. Chang M.C., Chang Y.T., Su T.C., Yang W.S., Chen C.L., Tien Y.W., Liang P.C., Wei S.C., Wong J.M. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas 2007, 35:16-21.
75. Tworoger S.S., Eliassen A.H., Kelesidis T., Colditz G.A., Willett W.C., Mantzoros C.S., Hankinson S.E. Plasma adiponectin concentrations and risk of incident breast cancer. J. Clin. Endocrinol. Metab. 2007, 92:1510-1516.
76. Grossmann M.E., Ray A., Nkhata K.J., Malakhov D.A., Rogozina O.P., Dogan S., Cleary M.P. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010, 29:641-653.
77. Stefan N., Vozarova B., Funahashi T., Matsuzawa Y., Weyer C., Lindsay R.S., Youngren J.F., Havel P.J., Pratley R.E., Bogardus C., Tataranni P.A. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
78. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta 2007, 380:24-30.
79. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
80. Zakikhani M., Dowling R.J., Sonenberg N., Pollak M.N. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev. Res. (Phila) 2008, 1:369-375.
81. Brakenhielm E., Veitonmaki N., Cao R., Kihara S., Matsuzawa Y., Zhivotovsky B., Funahashi T., Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 2004, 101:2476-2481.
82. Margetic S., Gazzola C., Pegg G.G., Hill R.A. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 2002, 26:1407-1433.
83. Cascio S., Bartella V., Auriemma A., Johannes G.J., Russo A., Giordano A., Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 2008, 27:540-547.
84. White P.B., True E.M., Ziegler K.M., Wang S.S., Swartz-Basile D.A., Pitt H.A., Zyromski N.J. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J. Gastrointest. Surg. 2010.
85. Grossmann M.E., Ray A., Nkhata K.J., Malakhov D.A., Rogozina O.P., Dogan S., Cleary M.P. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010, 29:641-653.
86. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334:292-295.
87. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72:1605-1621.
88. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
89. van Kruijsdijk R.C., van der W.E., Visseren F.L. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2569-2578.
90. Ramos E.J., Xu Y., Romanova I., Middleton F., Chen C., Quinn R., Inui A., Das U., Meguid M.M. Is obesity an inflammatory disease?. Surgery 2003, 134:329-335.
91. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 2003, 112:1785-1788.
92. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
93. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Low-grade systemic inflammation in overweight children. Pediatrics 2001, 107:E13.
94. Fogarty A.W., Glancy C., Jones S., Lewis S.A., McKeever T.M., Britton J.R. A prospective study of weight change and systemic inflammation over 9y. Am. J. Clin. Nutr. 2008, 87:30-35.
95. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14:109-119.
96. Kim S., Keku T.O., Martin C., Galanko J., Woosley J.T., Schroeder J.C., Satia J.A., Halabi S., Sandler R.S. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008, 68:323-328.
97. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
98. Chavey C., Mari B., Monthouel M.N., Bonnafous S., Anglard P., Van O.E., Tartare-Deckert S. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem. 2003, 278:11888-11896.
99. Kulbe H., Thompson R., Wilson J.L., Robinson S., Hagemann T., Fatah R., Gould D., Ayhan A., Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007, 67:585-592.
100. Davies F.E., Rollinson S.J., Rawstron A.C., Roman E., Richards S., Drayson M., Child J.A., Morgan G.J. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J. Clin. Oncol. 2000, 18:2843-2851.
101. Il'yasova D., Colbert L.H., Harris T.B., Newman A.B., Bauer D.C., Satterfield S., Kritchevsky S.B. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2413-2418.
102. Bruce W.R., Wolever T.M., Giacca A. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr. Cancer 2000, 37:19-26.
103. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
104. Gago-Dominguez M., Castelao J.E., Pike M.C., Sevanian A., Haile R.W. Role of lipid peroxidation in the epidemiology and prevention of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2829-2839.
105. Gago-Dominguez M., Jiang X., Castelao J.E. Lipid peroxidation, oxidative stress genes and dietary factors in breast cancer protection: a hypothesis. Breast Cancer Res. 2007, 9:201.
106. Robertson R.P., Harmon J., Tran P.O., Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004, 53(SUPPL 1):S119-S124.
107. Katiyar S.K., Meeran S.M. Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling. Free Radic. Biol. Med. 2007, 42:299-310.
108. Dickson R.B., Thompson E.W., Lippman M.E. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J. Steroid Biochem. Mol. Biol. 1990, 37:305-316.
109. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
110. Pugeat M., Crave J.C., Elmidani M., Nicolas M.H., Garoscio-Cholet M., Lejeune H., Dechaud H., Tourniaire J. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J. Steroid Biochem. Mol. Biol. 1991, 40:841-849.
111. Siiteri P.K. Adipose tissue as a source of hormones. Am. J. Clin. Nutr. 1987, 45:277-282.
112. Kaaks R., Lukanova A., Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1531-1543.
113. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita H.B., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils C.H., Gonzalez C.A., Gurrea A.B., Critselis E., Khaw K.T., Krogh V., Lahmann P.H., Nagel G., Olsen A., Onland-Moret N.C., Overvad K., Palli D., Panico S., Peeters P., Quiros J.R., Roddam A., Thiebaut A., Tjonneland A., Chirlaque M.D., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 2005, 97:755-765.
114. Key T.J. Serum oestradiol and breast cancer risk. Endocr. Relat Cancer 1999, 6:175-180.
115. Gort E.H., Groot A.J., van der W.E., van Diest P.J., Vooijs M.A. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr. Mol. Med. 2008, 8:60-67.
116. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997, 57:5328-5335.
117. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
118. Marignol L., Coffey M., Lawler M., Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction?. Cancer Treat. Rev. 2008, 34:313-327.
119. Vaupel P., Hoeckel M. Predictive power of the tumor oxygenation status. Adv. Exp. Med. Biol. 1999, 471:533-539.
120. Feldmann H.J., Molls M., Vaupel P. Blood flow and oxygenation status of human tumors. Clinical investigations. Strahlenther. Onkol. 1999, 175:1-9.
121. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu. Rev. Med. 2010, 61:301-316.
122. Trayhurn P., Wang B., Wood I.S. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?. Br. J. Nutr. 2008, 100:227-235.
123. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1118-E1128.
124. Lolmede K., DeDurand S.F., Galitzky V.J., Lafontan M., Bouloumie A. Effects of hypoxia on the expression of factors in differentiated 3T3-F442A adipocytes. Int. J. Obes. Relat. Metab. Disord. 2003, 27:1187-1195.
125. Koda M., Sulkowska M., Kanczuga-Koda L., Cascio S., Colucci G., Russo A., Surmacz E., Sulkowski S. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. Ann. Oncol. 2007, 18(SUPPL 6):vi116-vi119.
126. Bartella V., Cascio S., Fiorio E., Auriemma A., Russo A., Surmacz E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res. 2008, 68:4919-4927.
127. Silha J.V., Krsek M., Sucharda P., Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obes. (Lond) 2005, 29:1308-1314.
128. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358:2039-2049.
129. CDC, 2007 National Diabetes Fact Sheet, Atlanta, GA, 2007. http://www.cdc.gov/diabetes/pubs/factsheet07.htm.
130. T.A. Chowdhury, Diabetes and cancer, QJM. (2010).
131. Giaginis C., Katsamangou E., Tsourouflis G., Zizi-Serbetzoglou D., Kouraklis G., Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med. Sci. Monit. 2009, 15:BR148-BR156.
132. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. Diab. Care 2010, 33:1674-1685.
133. Grote V.A., Becker S., Kaaks R. Diabetes mellitus type 2-an independent risk factor for cancer?. Exp. Clin. Endocrinol. Diabetes 2010, 118:4-8.
134. Schott S., Schneeweiss A., Sohn C. Breast cancer and diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2010.
135. Czyzyk A., Szczepanik Z. Diabetes mellitus and cancer. Eur. J. Intern. Med. 2000, 11:245-252.
136. Gullo L., Pezzilli R., Morselli-Labate A.M. Diabetes and the risk of pancreatic cancer. N. Engl. J. Med. 1994, 331:81-84.
137. Pezzilli R., Casadei R., Morselli-Labate A.M. Is type 2 diabetes a risk factor for pancreatic cancer?. JOP 2009, 10:705-706.
138. Everhart J., Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273:1605-1609.
139. Huxley R., Nsary-Moghaddam A., de Berrington G.A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 2005, 92:2076-2083.
140. Stevens R.J., Roddam A.W., Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br. J. Cancer 2007, 96:507-509.
141. Jamal M.M., Yoon E.J., Vega K.J., Hashemzadeh M., Chang K.J. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J. Gastroenterol. 2009, 15:5274-5278.
142. Chari S.T., Leibson C.L., Rabe K.G., Timmons L.J., Ransom J., de A.M., Petersen G.M. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008, 134:95-101.
143. Pannala R., Leirness J.B., Bamlet W.R., Basu A., Petersen G.M., Chari S.T. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008, 134:981-987.
144. Chodick G., Heymann A.D., Rosenmann L., Green M.S., Flash S., Porath A., Kokia E., Shalev V. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control 2010, 21:879-887.
145. Butler A.E., Galasso R., Matveyenko A., Rizza R.A., Dry S., Butler P.C. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010, 53:21-26.
146. Renehan A.G., Berster J.M. Insulin and cancer: report of the proceedings of the first international workshop, October 27-28, 2007, Dusseldorf, Germany. Pediatr. Endocrinol. Rev. 2008, 5:810-816.
147. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7:85-96.
148. Asano T., Yao Y., Shin S., McCubrey J., Abbruzzese J.L., Reddy S.A. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005, 65:9164-9168.
149. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., Reddy S.A. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem. Biophys. Res. Commun. 2005, 331:295-302.
150. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., Sawicki P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
151. Campbell P.T., Deka A., Jacobs E.J., Newton C.C., Hildebrand J.S., McCullough M.L., Limburg P.J., Gapstur S.M. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 2010, 139:1138-1146.
152. Simon D., Balkau B. Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab. 2010, 36:182-191.
153. Kornmann M., Maruyama H., Bergmann U., Tangvoranuntakul P., Beger H.G., White M.F., Korc M. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res. 1998, 58:4250-4254.
154. Nakamura K., Sasajima J., Mizukami Y., Sugiyama Y., Yamazaki M., Fujii R., Kawamoto T., Koizumi K., Sato K., Fujiya M., Sasaki K., Tanno S., Okumura T., Shimizu N., Kawabe J., Karasaki H., Kono T., Ii M., Bardeesy N., Chung D.C., Kohgo Y. Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS ONE 2010, 5:e8824.
155. Kolb S., Fritsch R., Saur D., Reichert M., Schmid R.M., Schneider G. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res. 2007, 67:4679-4686.
156. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van B.G., Samuel S., Kim M.P., Lim S.J., Ellis L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69:1951-1957.
157. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., DePinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
158. Lalau J.D., Race J.M. Lactic acidosis in metformin therapy. Drugs 1999, 58(SUPPL 1):55-60.
159. Lalau J.D., Race J.M. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999, 20:377-384.
160. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab. Care 2006, 29:254-258.
161. Heikkinen S., Auwerx J., Argmann C.A. PPARgamma in human and mouse physiology. Biochim. Biophys. Acta 2007, 1771:999-1013.
162. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diab. Care 2010, 33:322-326.
163. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diab. Care 2009, 32:1620-1625.
164. Monami M., Lamanna C., Balzi D., Marchionni N., Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009, 46:279-284.
165. Cazzaniga M., Bonanni B., Guerrieri-Gonzaga A., Decensi A. Is it time to test metformin in breast cancer clinical trials?. Cancer Epidemiol. Biomarkers Prev. 2009, 18:701-705.
166. Goodwin P.J., Ligibel J.A., Stambolic V. Metformin in breast cancer: time for action. J. Clin. Oncol. 2009, 27:3271-3273.
167. Martin-Castillo B., Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010, 9:1323.
168. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., Uchiyama T., Suzuki K., Iida H., Sakamoto Y., Yoneda K., Koide T., Tokoro C., Abe Y., Inamori M., Nakagama H., Nakajima A. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev. Res. (Phila) 2010, 3:1077-1083.
169. Jiralerspong S., Palla S.L., Giordano S.H., Meric-Bernstam F., Liedtke C., Barnett C.M., Hsu L., Hung M.C., Hortobagyi G.N., Gonzalez-Angulo A.M. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 2009, 27:3297-3302.
170. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
171. Anisimov V.N., Egormin P.A., Bershtein L.M., Zabezhinskii M.A., Piskunova T.S., Popovich I.G., Semenchenko A.V. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull. Exp. Biol. Med. 2005, 139:721-723.
172. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., Poroshina T.E., Semenchenko A.V., Provinciali M., Re F., Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 2005, 40:685-693.
173. Liu B., Fan Z., Edgerton S.M., Deng X.S., Alimova I.N., Lind S.E., Thor A.D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040.
174. Tomimoto A., Endo H., Sugiyama M., Fujisawa T., Hosono K., Takahashi H., Nakajima N., Nagashima Y., Wada K., Nakagama H., Nakajima A. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008, 99:2136-2141.
175. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-10812.
176. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006, 66:10269-10273.
177. Ben S., Laurent I.K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J.F., Le Marchand-Brustel Y., Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586.
178. Ben S., Le Marchand-Brustel I.Y., Tanti J.F., Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol. Cancer Ther. 2010, 9:1092-1099.
179. Feng Z., Hu W., de S.E., Teresky A.K., Jin S., Lowe S., Levine A.J. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67:3043-3053.
180. Guigas B., Bertrand L., Taleux N., Foretz M., Wiernsperger N., Vertommen D., Andreelli F., Viollet B., Hue L. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006, 55:865-874.
181. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
182. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., Kizaki H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 2008, 283:3979-3987.
183. Ersoy C., Kiyici S., Budak F., Oral B., Guclu M., Duran C., Selimoglu H., Erturk E., Tuncel E., Imamoglu S. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 2008, 81:56-60.
184. Lund S.S., Tarnow L., Stehouwer C.D., Schalkwijk C.G., Teerlink T., Gram J., Winther K., Frandsen M., Smidt U.M., Pedersen O., Parving H.H., Vaag A.A. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur. J. Endocrinol. 2008, 158:631-641.
185. Huang N.L., Chiang S.H., Hsueh C.H., Liang Y.J., Chen Y.J., Lai L.P. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation, IkappaB-alpha degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation. Int. J. Cardiol. 2009, 134:169-175.
186. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
187. Vazquez-Martin A., Oliveras-Ferraros C., Barco S.D., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 2010, 1:1.
188. Schneider M.B., Matsuzaki H., Haorah J., Ulrich A., Standop J., Ding X.Z., Adrian T.E., Pour P.M. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001, 120:1263-1270.
189. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009, 69:6539-6545.
190. Wang L.W., Li Z.S., Zou D.W., Jin Z.D., Gao J., Xu G.M. Metformin induces apoptosis of pancreatic cancer cells. World J. Gastroenterol. 2008, 14:7192-7198.
191. Rozengurt E., Sinnett-Smith J., Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 2010, 16:2505-2511.
192. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
193. Burns K.A., Vanden Heuvel J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 2007, 1771:952-960.
194. Zingarelli B., Sheehan M., Hake P.W., O'Connor M., Denenberg A., Cook J.A. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol. 2003, 171:6827-6837.
195. Auwerx J., Martin G., Guerre-Millo M., Staels B. Transcription, adipocyte differentiation, and obesity. J. Mol. Med. 1996, 74:347-352.
196. Papi A., Rocchi P., Ferreri A.M., Orlandi M. RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells. Cancer Lett. 2010.
197. Crosby M.B., Svenson J., Gilkeson G.S., Nowling T.K. A novel PPAR response element in the murine iNOS promoter. Mol. Immunol. 2005, 42:1303-1310.
198. Tontonoz P., Hu E., Spiegelman B.M. Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev. 1995, 5:571-576.
199. Brun R.P., Spiegelman B.M. PPAR gamma and the molecular control of adipogenesis. J. Endocrinol. 1997, 155:217-218.
200. Carter A.B., Misyak S.A., Hontecillas R., Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma. PPAR Res. 2009, 2009:498352.
201. Carter J.C., Church F.C. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1. PPAR Res. 2009, 2009:345320.
202. Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., Genua M., Vigneri R., Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006, 147:4463-4475.
203. Ramos-Nino M.E., MacLean C.D., Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med. 2007, 5:17.
204. Koro C., Barrett S., Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol. Drug Saf. 2007, 16:485-492.
205. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 2010, 47:87-95.
206. Roman J. Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J. Investig. Med. 2008, 56:528-533.
207. Takahashi H., Hosono K., Uchiyama T., Sugiyama M., Sakai E., Endo H., Maeda S., Schaefer K.L., Nakagama H., Nakajima A. PPARgamma ligand as a promising candidate for colorectal cancer chemoprevention: a pilot study. PPAR Res. 2010.
208. Kristiansen G., Jacob J., Buckendahl A.C., Grutzmann R., Alldinger I., Sipos B., Kloppel G., Bahra M., Langrehr J.M., Neuhaus P., Dietel M., Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin. Cancer Res. 2006, 12:6444-6451.
209. Eibl G., Wente M.N., Reber H.A., Hines O.J. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 2001, 287:522-529.
210. Eibl G. The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res. 2008, 2008:326915.
211. Knauer S.K. Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas. J. Oncol. 2009, 2009:349205.
212. Panigrahy D., Shen L.Q., Kieran M.W., Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin. Investig. Drugs 2003, 12:1925-1937.
213. Takeuchi Y., Takahashi M., Sakano K., Mutoh M., Niho N., Yamamoto M., Sato H., Sugimura T., Wakabayashi K. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Carcinogenesis 2007, 28:1692-1696.
214. Dolezalova R., Haluzik M.M., Bosanska L., Lacinova Z., Kasalova Z., Stulc T., Haluzik M. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol. Res. 2007, 56:741-748.
215. Quinn C.E., Hamilton P.K., Lockhart C.J., McVeigh G.E. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br. J. Pharmacol. 2008, 153:636-645.
216. Rumi M.A., Ishihara S., Kazumori H., Kadowaki Y., Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr. Med. Chem. Anticancer Agents 2004, 4:465-477.
217. Liu J., Lu H., Huang R., Lin D., Wu X., Lin Q., Wu X., Zheng J., Pan X., Peng J., Song Y., Zhang M., Hou M., Chen F. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother. Pharmacol. 2005, 56:400-408.
218. Nagata D., Yoshihiro H., Nakanishi M., Naruyama H., Okada S., Ando R., Tozawa K., Kohri K. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect. Prev. 2008, 32:259-266.
219. Nunez N.P., Liu H., Meadows G.G. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett. 2006, 236:133-141.
220. Takashima T., Fujiwara Y., Higuchi K., Arakawa T., Yano Y., Hasuma T., Otani S. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int. J. Oncol. 2001, 19:465-471.
221. Zand H., Rhimipour A., Bakhshayesh M., Shafiee M., Nour M., I, Salimi S. Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells. Mol. Cell. Biochem. 2007, 304:71-77.
222. Mansure J.J., Nassim R., Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol. Ther. 2009, 8:6-15.
223. Panigrahy D., Huang S., Kieran M.W., Kaipainen A. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol. Ther. 2005, 4:687-693.
224. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., Dello R.C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem. Pharmacol. 2005, 70:177-188.
225. Simpson-Haidaris P.J., Pollock S.J., Ramon S., Guo N., Woeller C.F., Feldon S.E., Phipps R.P. Anticancer role of PPARgamma agonists in hematological malignancies found in the vasculature, marrow, and eyes. PPAR Res. 2010, 2010:814609.
226. Feng Y.H., Velazquez-Torres G., Gully C., Chen J., Lee M.H., Yeung S.C. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. J. Cell Mol. Med. 2010.
227. Jin T., George F., I., Sun J. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell. Signal. 2008, 20:1697-1704.
228. DeSano J.T., Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J. 2009, 11:682-692.
229. Perera R.J., Ray A. MicroRNAs in the search for understanding human diseases. BioDrugs. 2007, 21:97-104.
230. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009.
231. Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12:2171-2176.
232. Li Y., Kong D., Wang Z., Sarkar F.H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27:1027-1041.
233. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 13:57-66.
234. Kent O.A., Mullendore M., Wentzel E.A., Lopez-Romero P., Tan A.C., Alvarez H., West K., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol. Ther. 2009, 8:2013-2024.
235. Rachagani S., Kumar S., Batra S.K. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett. 2010, 292:8-16.
236. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
237. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
238. Olson P., Lu J., Zhang H., Shai A., Chun M.G., Wang Y., Libutti S.K., Nakakura E.K., Golub T.R., Hanahan D. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009, 23:2152-2165.
239. He A., Zhu L., Gupta N., Chang Y., Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 2007, 21:2785-2794.
240. Heneghan H.M., Miller N., Kerin M.J. Role of microRNAs in obesity and the metabolic syndrome. Obes. Rev. 2010, 11:354-361.
241. Kong L., Zhu J., Han W., Jiang X., Xu M., Zhao Y., Dong Q., Pang Z., Guan Q., Gao L., Zhao J., Zhao L. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2010.
242. Kolfschoten I.G., Roggli E., Nesca V., Regazzi R. Role and therapeutic potential of microRNAs in diabetes. Diabetes Obes. Metab 2009, 11(SUPPL 4):118-129.
243. Lovis P., Roggli E., Laybutt D.R., Gattesco S., Yang J.Y., Widmann C., Abderrahmani A., Regazzi R. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 2008, 57:2728-2736.
244. Li Y., Vandenboom T.G., Wang Z., Kong D., Ali S., Philip P.A., Sarkar F.H. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70:1486-1495.
245. Herrera B.M., Lockstone H.E., Taylor J.M., Ria M., Barrett A., Collins S., Kaisaki P., Argoud K., Fernandez C., Travers M.E., Grew J.P., Randall J.C., Gloyn A.L., Gauguier D., McCarthy M.I., Lindgren C.M. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010, 53:1099-1109.
246. Lynn F.C. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol. Metab. 2009, 20:452-459.